TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00728195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Study: NCT01126281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT04635254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halophites-based cream 24 hours
Description: The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halophites-based cream 48 hours
Description: The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream 24 hours
Description: A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream 48 hours
Description: A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Histamine 1%
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Histamine 1%
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cowhage
Description: The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study: NCT00528411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Tablets
Description: Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
Study: NCT01753986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention plus Standard Batterer Intervention
Description: Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Improvement Intervention plus Standard Batterer Intervention
Description: General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
Study: NCT00528411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel (over encapsulated) capsule
Description: Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Tablets
Description: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Tablets
Description: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablets
Description: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
Study: NCT04635254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cowhage
Description: The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study: NCT03745872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Assessment
Description: Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
Study: NCT02283905

Intervention type: DRUG
Group type: OTHER
Intervention: amphotericin-B
Description: continuously infused

Intervention type: DRUG
Group type: OTHER
Intervention: voriconazole
Description: intravenously or orally administered
Study: NCT00784888

Intervention type: OTHER
Intervention: Aromatase inhibitors
Description: non-interventional study
Study: NCT01032603

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral lateral rectus recession (BLRc)
Description: Bilateral lateral rectus recession surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral lateral rectus recession with medial rectus resection (R&R)
Description: A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
Study: NCT02562300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
Study: NCT02209792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 20 mg
Study: NCT00191945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02777203

Intervention type: DEVICE
Group type: OTHER
Intervention: EcoSac 400 ECO-T
Description: Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
Study: NCT02763813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst (propulsion type oral appliance)
Description: Oral appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retention type appliance (ORM)
Study: NCT04905524

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: VIOME Precision Nutrition Program
Description: Diet and supplements recommendations
Study: NCT00703274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT DC
Description: PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
Study: NCT03028129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 900 milligrams
Description: Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
Study: NCT01042587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exposure to bright light
Description: Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
Study: NCT03537937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower SpO2 Target
Description: SpO2 target 90% (range 88-92%)
Study: NCT04166916

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM acoustic stimulation
Description: This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
Study: NCT03423381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 1
Description: Cereal products based on rye, barley, wheat, oat, and corn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 2
Description: Cereal products based on rye, barley, wheat, oat, and corn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 3
Description: Cereal products based on rye, barley, wheat, oat, and corn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 4
Description: Cereal products based on rye, barley, wheat, oat, and corn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 5
Description: Cereal products based on rye, barley, wheat, oat, and corn

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: A cereal based product with low concentrations of df
Study: NCT03537937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate SpO2 Target
Description: SpO2 target 94% (range 92-96%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher SpO2 Target
Description: SpO2 target 98% (range 96-100%)
Study: NCT01620801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8-hFIX19
Description: One-time IV vector administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8-hFIX19
Description: One-time IV vector administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8-hFIX19
Description: One-time IV vector administration.
Study: NCT03038516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
Study: NCT04458974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).
Study: NCT03038516

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
Study: NCT00721357

Intervention type: BEHAVIORAL
Intervention: Treadmill walking
Description: Subjects will perform treadmill walking at a self-selected velocity

Intervention type: BEHAVIORAL
Intervention: Treadmill walking
Description: Subjects will perform treadmill walking at a self-selected velocity

Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy
Description: Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)

Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy
Description: Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
Study: NCT02507050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: To start Ivabradine 6 weeks prior to PCI.
Study: NCT01002040

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arepanrix
Description: Group A receives one dose of Arepanrix
Study: NCT01186510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung perfusion
Description: see literature of proceeding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no lung perfusion
Description: see literature of proceeding
Study: NCT01002040

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arepanrix
Description: Group B receives 2 doses of Arepanrix 3 weeks apart
Study: NCT03344562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES
Description: Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
Study: NCT03620240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
Study: NCT02113592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain program
Description: Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
Study: NCT01803204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet - Preoperative Educational
Description: the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
Study: NCT03041597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of implants
Description: surgical procedure and placement of implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of implants
Description: surgical procedure and placement of implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: cone-anchored implant supported removable dental prostheses placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional loading
Description: cone-anchored implant supported removable dental prostheses placement in 3mo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankylos implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankylos implant
Study: NCT01118702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin-SR
Description: 3-20mg tablets, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: one 54mg tablet, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo-Methylphenidate ER-C
Description: one 54mg tablet, once
Study: NCT04009343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
Study: NCT01611649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing dairy lipids and plant oils
Description: 4 months consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing plant oils
Description: 4 months consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing dairy lipids and plant oils, DHA+ARA
Description: 4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
Study: NCT00957775

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered ACRA
Description: Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
Study: NCT01042587

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low luminosity red light
Description: Low level red light should not entrain circadian rhythm and will serve as a placebo control
Study: NCT00768846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor Resolute Stent
Description: Zotarolimus-eluting Endeavor Resolute Stent
Study: NCT02698839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme
Description: Stent platform: cobalt-chromium alloy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BuMA™
Description: Stent platform: stainless steel
Study: NCT00935597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
Description: Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
Study: NCT03344562

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CES
Description: Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
Study: NCT01287988

Intervention type: DRUG
Intervention: ocriplasmin
Description: Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007

Intervention type: DRUG
Intervention: placebo
Description: Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007